Latest filing published 01 Oct 2020 for LENSAR, Inc., €83k.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -15.6%Entry US$9.00 · Close at T+365 US$7.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
PDL Biopharma, Inc.: trading record in brief
Filings by PDL Biopharma, Inc. span 2 companies, the busiest being Evofem Biosciences, Inc. and LENSAR, Inc. Over a trading history stretching from 10 June 2019 to 1 October 2020, the count stands at 4 filings.
Purchases make up the whole of the open-market record (2 purchases, €26.6M). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2020 to date brings 1 purchase and no sales.
Most recently, on 1 October 2020, the filings show an open-market purchase worth €83k in LENSAR, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to PDL Biopharma, Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 8,703 shares@ US$11.16100.0% of flowCommon StockSEC:0000899243-20-026691:0Canonical exit: 28 Dec 2020 (T+90)
- 8,667,397 shares0Common StockSEC:0000899243-20-026691:1
- 13,333,334 shares0Common StockSEC:0000899243-20-014185:0
- 6,666,667 shares@ US$4.50Common StockSEC:0000899243-19-016240:0Canonical exit: 8 Sept 2019 (T+90)
4 of 4 declarations
